Latest Global Contracts News

PainChek has achieved FDA regulatory clearance enabling its device to qualify for US Remote Therapeutic Monitoring reimbursement, positioning the company for significant growth in the expanding US healthcare market. The company also reports strong global licence growth and a solid pipeline across multiple regions.

RocketBoots Limited has successfully raised A$7 million through a placement to accelerate its international expansion following a transformative global contract. The capital injection aims to scale its AI-driven loss-prevention platform and convert a robust enterprise pipeline.

Vulcan Energy has awarded a €72 million EPCM contract to a Sedgman and HOCHTIEF joint venture for its Phase One Lionheart Project, aiming to produce 24,000 tonnes of lithium hydroxide annually to fuel half a million electric vehicles.

Comms Group Limited reported a steady FY25 with revenue growth and a strong start to FY26, driven by the recent TasmaNet acquisition and expanding global contracts. The company is targeting over $75 million in annualised revenue and aims to boost EBITDA to $9-10 million.

Paradigm Biopharmaceuticals has drawn down US$5 million under its convertible note facility to fund the accelerated expansion of its global Phase 3 trial for knee osteoarthritis treatment.

PainChek has secured FDA De Novo clearance for its Adult App, opening immediate access to a $175 million AUD US long-term care market and advancing its Infant App commercialization targeting a $15 billion AUD global opportunity.

SenSen Networks has secured $2 million in new contracts across Singapore, the USA, and Australia, reinforcing its position as a leader in Live Awareness AI solutions. The company also strengthened its balance sheet with $1.5 million cash received from a recent Montreal project.

Acusensus Limited reported a 20% increase in revenue to $59.35 million for FY25, driven by new and expanded contracts across Australia, New Zealand, the US, and the UK. However, net losses widened by 72.3%, reflecting higher operating expenses and ongoing litigation costs.

EPX Limited reports robust FY25 growth with a 10% rise in Annual Contract Value and a 35% increase in site numbers, driven by strategic sales restructuring and key new partnerships.

Neurizon Therapeutics has received positive feedback from the FDA on its plan to resolve the clinical hold on its ALS drug candidate NUZ-001, with key preclinical studies completed ahead of schedule. The company aims to resume clinical trials in late 2025.

Way2VAT has secured a significant three-year contract with global real estate giant JLL, deploying its AI-driven VAT recovery and compliance platform across 25 entities worldwide. This deal positions Way2VAT as a key player in automated VAT solutions for multinational corporations.

Harvest Technology Group reported a 19% improvement in normalized EBITDA for Q3 FY25 alongside a $1.6 million capital raise, reinforcing its strategic plan to achieve profitability by FY27.